LEXXW - Lexaria Technology Generates Positive Stability Testing for World-Class Ready to Drink CBD Beverages
(TheNewswire)
-
- DehydraTECH TM CBD-Beverage Demonstrates 93.4% PotencyOne Year After Production
- Lexaria’s NanoemulsificationProcessing Technique Ensures Content Uniformity and Homogeneity of CBDDistribution Without Need for Physical Mixing
Kelowna, British Columbia – TheNewswire - March 24, 2021 –Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or“Lexaria”), a global innovator in drug delivery platforms,announced positive results from its extended stability testing, whichhas reported unparalleled stability for bottled CBD-containingbeverages prepared using its technology.
Lexaria’s patented DehydraTECH TM CBD (cannabidiol) nanoemulsificationformulation and processing techniques are responsible for the testedbeverages maintaining their CBD content whichwas verified at 93.4% of target potency one year after production andalso evidenced excellent microbial purity over this period.
The DehydraTECH-processed ready-to-drink (“RTD”)beverages were also tested for content uniformity and homogeneity ofCBD distribution, and demonstrated less than 1% variability in CBDpotency in fractions sampled from the top, middle and bottom of thebeverage formulation without physical mixing or agitation.
“I love reminding people that Lexaria’s firstpatent was awarded in 2016 for CBD-infused beverages and consumableliquids,” said Chris Bunka, CEO of Lexaria. “Our technology wasworking in cannabinoid beverages years before the big cannabiscompanies started spending hundreds of millions of dollars trying tofigure it out.”
In February 2020, Lexaria prepared proprietary,patented DehydraTECH-powered CBD-based nanoemulsions for Nic’sBeverages, owners of the Nic’s Cold Brew brand, and has beensubjecting samples from the commercial bottling run to real-world,long-term stability testing that resulted in average potency of 93.4%after one year; complete uniformity; and no microbial growth. Testingwill continue until such time as Lexaria’s formulation no longerremains stable, although the Company cannot know when that mightbe.
“I am incredibly happy with the world-class resultswe have experienced using DehydraTECH in our CBD beverages, said JohnGoodpasture, CEO of Nic’s Beverages. “The coffee flavour and aromaexperience are exceptional from the moment you open the bottle andremain so one year later.”
Beverages containing cannabinoids often need to beshaken prior to use and tend to degrade overtime , sometimes dramatically so.There have been reports of beverages sold that contain only a tinyfraction of the cannabinoids listed on the product label, whether dueto inadequatemanufacturing techniques or timedecay . Lexaria’s data demonstrateexceptional effectiveness in integrating CBD into RTD beverages in astable and homogenously distributed manner over time without the needfor physical mixing or agitation before consumption.
Lexaria’s DehydraTECH technology has been clinicallyverified to deliver a significantly higher fraction of CBD toconsumers’ blood circulation in a shorter period of time. Othertesting has also evidenced significantly higher brain perfusion ofDehydraTECH CBD, which is important for human conditions that arepartially or entirely centrally mediated (regulated by the brain orcentral nervous system).
Lexaria Bioscience Corp.’s proprietary drug deliverytechnology, DehydraTECH™, improves the way active pharmaceuticalingredients (APIs) enter the bloodstream by promoting healthier oralingestion methods and increasing the effectiveness of fat-solubleactive molecules, thereby lowering overall dosing. The Company’stechnology can be applied to many different ingestible productformats, including foods, beverages, oral suspensions, tablets, andcapsules. DehydraTECH has repeatedly demonstrated since 2016 withcannabinoids and nicotine the ability to increase bio-absorption by upto 5-10x, reduce time of onset from 1 - 2 hours to minutes, and maskunwanted tastes; and is planned to be further evaluated for orallyadministered bioactive molecules, including anti-virals, cannabinoids,vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), andnicotine. Lexaria has licensed DehydraTECH to multiple companiesincluding a world-leading tobacco producer for the development ofsmokeless, oral-based nicotine products and for use in industries thatproduce cannabinoid beverages, edibles, and oral products. Lexariaoperates a licensed in-house research laboratory and holds a robustintellectual property portfolio with 18 patents granted andapproximately 60 patents pending worldwide. For more information,please visit www.lexariabioscience.com .
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press releaseincludes forward-looking statements. Statements as such term isdefined under applicable securities laws. These statements may beidentified by words such as "anticipate," "if,""believe," "plan," "estimate,""expect," "intend," "may,""could," "should," "will," and othersimilar expressions. Such forward-looking statements in this pressrelease include, but are not limited to, statements by the companyrelating the Company’s ability to carry out research initiatives,receive regulatory approvals or grants or experience positive effectsor results from any research or study. Such forward-looking statementsare estimates reflecting the Company's best judgment based uponcurrent information and involve a number of risks and uncertainties,and there can be no assurance that the Company will actually achievethe plans, intentions, or expectations disclosed in theseforward-looking statements. As such, you should not place unduereliance on these forward-looking statements. Factors which could cause actualresults to differ materially from those estimated by the Companyinclude, but are not limited to, government regulation and regulatoryapprovals, managing and maintaining growth, the effect of adversepublicity, litigation, competition, scientific discovery, the patentapplication and approval process, potential adverse effects arisingfrom the testing or use of products utilizingthe DehydraTECH technology, the Company’s ability to maintainexisting collaborations and realize the benefits thereof, delays orcancellations of planned R&D that could occur related to pandemicsor for other reasons, and other factors which may be identified fromtime to time in the Company's public announcements and periodicfilings with the US Securities and Exchange Commission on EDGAR. Thereis no assurance that any of Lexaria’s postulated uses, benefits, oradvantages for the patented and patent-pending technology will in factbe realized in any manner or in any part. No statement herein has beenevaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat,cure or prevent any disease. Any forward-looking statements containedin this release speak only as of the date hereof, and the Companyexpressly disclaims any obligation to update any forward-lookingstatements contained herein, whether as a result of any newinformation, future events, changed circumstances or otherwise, exceptas otherwise required by law.
TheCSE has not reviewed and does not accept responsibility for theadequacy or accuracy of this release.
INVESTOR CONTACT:
Copyright (c) 2021 TheNewswire - All rights reserved.